Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERRUPT: Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users
NCT03118297Phase 3Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in abnormal uterine bleeding (AUB) comparing Ulipristal Acetate with Placebo (2 arms). Primary endpoint: Number of Bleeding and Spotting Days at 30 days. Started May 2017; status: completed.
02
Drugs
ulipristal
03
Conditions
abnormal uterine bleeding (AUB)
Beyond the preview
Go deeper on NCT03118297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118297.